scholarly journals Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Yoga Yuniadi ◽  
Yuyus Kusnadi ◽  
Lakshmi Sandhow ◽  
Rendra Erika ◽  
Dicky A. Hanafy ◽  
...  

Background. Proangiogenic Hematopoietic Cells (PHC) which comprise diverse mixture of cell types are able to secrete proangiogenic factors and interesting candidate for cell therapy. The aim of this study was to seek for benefit in implantation of PHC on functional improvement in end stage coronary artery disease patients with advanced heart failure.Methods. Patients with symptomatic heart failure despite guideline directed medical therapy and LVEF less than 35% were included. Peripheral blood mononuclear cells were isolated, cultivated for 5 days, and then harvested. Flow cytometry and cell surface markers were used to characterize PHC. The PHC were delivered retrogradely via sinus coronarius. Echocardiography, myocardial perfusion, and clinical and functional data were analyzed up to 1-year observation.Results. Of 30 patients (56.4±7.40 yo) preimplant NT proBNP level is5124.5±4682.50 pmol/L. Harvested cells characterized with CD133, CD34, CD45, and KDR showed0.87±0.41,0.63±0.66,99.00±2.60, and3.22±3.79%, respectively. LVEF was improved (22±5.68versus26.8±7.93,p<0.001) during short and long term observation. Myocardial perfusion significantly improved 6 months after treatment. NYHA Class and six-minute walk test are improved during short term and long term follow-up.Conclusion. Expanded peripheral blood PHC implantation using retrograde delivery approach improved LV systolic function, myocardial perfusion, and functional capacity.

2003 ◽  
Vol 91 (4) ◽  
pp. 497-500 ◽  
Author(s):  
Richard M. de Jong ◽  
Paul K. Blanksma ◽  
Jan H. Cornel ◽  
A.d F.M. Van den Heuvel ◽  
Hans-Marc J. Siebelink ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Haozhang Huang ◽  
Jin Liu ◽  
Yan Liang ◽  
Kunming Bao ◽  
Linfang Qiao ◽  
...  

Background: Hypochloremia is an independent predictor for mortality in patients with coronary artery disease (CAD) but whether the same correlation exists in CAD patients with congestive heart failure (CHF) is unclear.Methods: This is an analysis of data stored in the databases of the CIN-I [a registry of Cardiorenal Improvement (NCT04407936) in China from January 2007 to December 2018] and Medical Information Mart for Intensive Care (MIMIC)-III. CAD patients with CHF were included. The outcome measures were 90-day all-cause mortality (ACM) and long-term ACM.Results: Data from 8,243 CAD patients with CHF were analyzed. We found that 10.2% of the study population had hypochloremia (Cl− &lt;98 mmol/L) in CIN-I (n = 4,762) and 20.1% had hypochloremia in MIMIC-III (n = 3,481). Patients suffering from hypochloremia were, in general, older and had a higher prevalence of comorbidities. After adjustment for confounders, hypochloremia remained a significant predictor of short-term mortality risk [90-day ACM: adjusted hazard ratio (aHR), 1.69; 95% CI, 1.27–2.25; P &lt; 0.001 in CIN-I, and 1.36 (1.17–1.59); P &lt; 0.001 in MIMIC-III]. Hypochloremia was also associated with long-term mortality [aHR, 1.26; 95% CI, 1.06–1.50; P = 0.009 in CIN-I, and 1.48 (1.32–1.66); P &lt; 0.001 in MIMIC-III]. Prespecified subgroup analyses revealed an association of hypochloremia with long-term ACM to be attenuated slightly in the women of the two databases (P interaction &lt; 0.05).Conclusions: Hypochloremia is independently associated with higher short-term and long-term ACM. Further studies are needed to determine if early preventive measurements and active intervention of hypochloremia can reduce the mortality risk of CAD patients with CHF.


2020 ◽  
Vol 7 (5) ◽  
pp. 2468-2478
Author(s):  
Chris R. Bain ◽  
Mark Ziemann ◽  
Antony Kaspi ◽  
Abdul Waheed Khan ◽  
Rachael Taylor ◽  
...  

2011 ◽  
Vol 3 (1) ◽  
pp. 63 ◽  
Author(s):  
Phil Rasmussen

SUMMARY MESSAGE: Some evidence exists for hawthorn extracts having beneficial effects when taken concurrently with optimal medication for the treatment of mild chronic heart failure, although further long-term studies involving large numbers of patients are needed. Evidence is less convincing for its efficacy in hypertension, angina, coronary artery disease, arrhythmias and other cardiac conditions. As with all herbal medicines, different hawthorn products vary in their pharmaceutical quality, and the implications of this for dosage, efficacy and safety should be considered.


1999 ◽  
Vol 63 (2) ◽  
pp. 73-78 ◽  
Author(s):  
Li Linxue ◽  
Ryuji Nohara ◽  
Shigeru Makita ◽  
Ryohei Hosokawa ◽  
Tatsuhiko Hata ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document